The following represents disclosure information provided by authors of this abstract. The Genitourinary Cancers Symposium Program Committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered self-held and compensated unless otherwise noted. Employment/Leadership relationships are considered compensated employment unless otherwise noted. L = Leadership, U = Uncompensated, I = Immediate Family Member, B = Both Myself and Immediate Family Member, Inst = My Institution
Results of a feasibility study of I-124 girentuximab in metastatic clear cell renal cell carcinoma (m ccRCC).
Stephen Michael Keefe
Research Funding - Bristol-Myers Squibb
Mark Alan Rosen
No relevant relationships to disclose
Janelle Robinson
Research Funding - Bristol-Myers Squibb
Karen McGibney
Research Funding - Bristol-Myers Squibb
Amy Marshall
Research Funding - Bristol-Myers Squibb
Ronac Mamtani
No relevant relationships to disclose
David J. Vaughn
No relevant relationships to disclose
Peter J. O'Dwyer
No relevant relationships to disclose
Naomi B. Haas
No relevant relationships to disclose
Daniel A. Pryma
No relevant relationships to disclose